RESEARCH USE ONLY. Reference data for laboratory research. Not medical advice; not for human consumption.
Peptijournal
Calc

Compare compounds

Pick up to 3 compounds to see protocols, mechanisms, study endpoints and safety findings side by side.

PopularRetatrutide vs TirzepatideSemaglutide vs TirzepatideSemaglutide vs RetatrutideBPC-157 vs TB-500BPC-157 vs GHK-CuSermorelin vs Tesamorelin
VIP
Same goal
Include when printing

Only affects the printed page / PDF. The research-use-only notice always prints.

Protocol01
VIP

Cognitive

Vials · 5 / 10 mg

01Protocol

Vials
5 / 10 mg
Dosing data
Lab reference — not listed

02Quick calculator

Draw (100u)

—

Concentration

—

mg/mL

03Mechanism of action

Vasoactive intestinal peptide (VIP; aviptadil as a drug) is a 28-amino-acid neuropeptide acting on VPAC1/VPAC2 receptors, causing vasodilation and anti-inflammatory effects in lung and gut.

04Study endpoints

  • RCT in critical COVID-19 respiratory failure: the primary endpoint was not met, though survival from respiratory failure at day 60 was reported as improved.
  • Inhaled VIP in pulmonary hypertension: a modest, short-lived drop in pulmonary vascular resistance without lowering systemic blood pressure.

05Safety & regulatory findings

  • Not approved by the FDA or EMA for any indication; research-grade material is not a medicine.
  • No drug-related serious adverse events were reported in the COVID-19 trial; inhaled VIP caused no side effects in the pulmonary hypertension study.

06Citations

2 references · view